178 related articles for article (PubMed ID: 27663594)
21. ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Si X; Liu Y; Lv J; Ding H; Zhang XA; Shao L; Yang N; Cheng H; Sun L; Zhu D; Yang Y; Li A; Han X; Sun Y
Oncotarget; 2016 Apr; 7(15):20966-80. PubMed ID: 26980709
[TBL] [Abstract][Full Text] [Related]
22. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines.
Noordhuis P; Laan AC; van de Born K; Honeywell RJ; Peters GJ
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31344863
[TBL] [Abstract][Full Text] [Related]
23. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
24. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
25. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
26. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
[TBL] [Abstract][Full Text] [Related]
27. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
28. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
30. Targeting DNA Repair in Ovarian Cancer Treatment Resistance.
Wong-Brown MW; van der Westhuizen A; Bowden NA
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):518-526. PubMed ID: 32253106
[TBL] [Abstract][Full Text] [Related]
31. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK; Simes RJ; Brown C; Gebski V; Pfisterer J; Swart AM; Berton-Rigaud D; Plante M; Skeie-Jensen T; Vergote I; Schauer C; Pisano C; Parma G; Baumann K; Ledermann JA; Pujade-Lauraine E; Bentley J; Kristensen G; Belau A; Nankivell M; Canzler U; Lord SJ; Kurzeder C; Friedlander M
Ann Oncol; 2013 Apr; 24(4):937-43. PubMed ID: 23104722
[TBL] [Abstract][Full Text] [Related]
32. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
33. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
Özeş AR; Miller DF; Özeş ON; Fang F; Liu Y; Matei D; Huang T; Nephew KP
Oncogene; 2016 Oct; 35(41):5350-5361. PubMed ID: 27041570
[TBL] [Abstract][Full Text] [Related]
34. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
35. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
36. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
[TBL] [Abstract][Full Text] [Related]
37. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Clin Cancer Res; 2017 Jul; 23(14):3610-3618. PubMed ID: 28137924
[No Abstract] [Full Text] [Related]
38. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
39. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
40. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
